{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT04243681",
      "OrgStudyIdInfo": {
        "OrgStudyId": "ECR/346/Inst/AP/2013"
      },
      "Organization": {
        "OrgFullName": "Asian Institute of Gastroenterology, India",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "Combination of Autologous MSC and HSC Infusion in Patients With Decompensated Cirrhosis",
      "OfficialTitle": "Combination of Autologous Mesenchymal and Hematopoietic Stem Cell Infusion in Patients With Decompensated Cirrhosis: A Pilot Study"
    },
    "StatusModule": {
      "StatusVerifiedDate": "January 2020",
      "OverallStatus": "Completed",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "July 1, 2019",
        "StartDateType": "Actual"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "August 1, 2020",
        "PrimaryCompletionDateType": "Actual"
      },
      "CompletionDateStruct": {
        "CompletionDate": "September 1, 2020",
        "CompletionDateType": "Actual"
      },
      "StudyFirstSubmitDate": "August 14, 2019",
      "StudyFirstSubmitQCDate": "January 24, 2020",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "January 28, 2020",
        "StudyFirstPostDateType": "Actual"
      },
      "LastUpdateSubmitDate": "October 20, 2020",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "October 22, 2020",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Sponsor"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Asian Institute of Gastroenterology, India",
        "LeadSponsorClass": "OTHER"
      }
    },
    "OversightModule": {
      "OversightHasDMC": "No",
      "IsFDARegulatedDrug": "No",
      "IsFDARegulatedDevice": "No"
    },
    "DescriptionModule": {
      "BriefSummary": "Though the results of autologous CD34+ cell infusion and MSC in independent studies have shown promise, yet they are yet to reach the desired long term outcome. The possible postulation for this is possibly because when using autologous CD34+ cell infusion, the inflammatory milieu of the liver may not be conducive for sustained effects of the mobilized CD 34+ cells. MSC have immunomodulatory effect (ref) and may improve the liver environment making it more beneficial for the CD34+ cells to function and survive. In addition, MSC has ben shown to produce hepatocyte growth factor which is protective against liver injury and beneficial for liver regeneration (shown in above tables). However, it remains to be understood how MSCs promote liver stem stem cells to differentiate into hepatocytes or expand the residual hepatocyte population. MSC can also directly inhibit the activation of hepatic stellate cells, the main source of extracellular matrix via MSC derived IL 10 and TNF-Î±and may also induce hepatic stellate cell apoptosis. Current lacunae in cell based therapy is based on the poor consensus and understanding on the best type of cells to be used, the ideal number of cells, the most appropriate route of administration and the need for repeat dosing . The concept that combination of autologous hematopoietic and mesenchymal stem cells infusion may be more beneficial than infusing any one of them alone has been discussed in many scientific forums but there are no study till date to either see the safety as well as the efficacy of this proof of concept .\n\nWith this above background data, we propose a study design which will be a safety study for combination use of autologous CD34+ and MSC"
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Cirrhosis, Liver"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "Mesenchymal Stem Cell",
          "Hematopoetic Stem cell",
          "Autologous transfusion"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 4"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "Non-Randomized",
        "DesignInterventionModel": "Parallel Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "None (Open Label)"
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "5",
        "EnrollmentType": "Actual"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "Combination MSC and HSC",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Patient will receive a combination of mesenchymal and Hematopoetic stem cell through hepatic artery under fluroscopic guidance",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Combination Product: CD 34 and MSC infusion"
              ]
            }
          },
          {
            "ArmGroupLabel": "Standard of care for Cirrhosis management",
            "ArmGroupType": "Active Comparator",
            "ArmGroupDescription": "Diuretics, Hepatoprotective agents and Lactulose",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Drug: Standard of care for Cirrhosis management"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Combination Product",
            "InterventionName": "CD 34 and MSC infusion",
            "InterventionDescription": "Combination of stem cells",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Combination MSC and HSC"
              ]
            },
            "InterventionOtherNameList": {
              "InterventionOtherName": [
                "Stem cell infusion"
              ]
            }
          },
          {
            "InterventionType": "Drug",
            "InterventionName": "Standard of care for Cirrhosis management",
            "InterventionDescription": "Drugs used for Cirrhosis management such as Diuretics, Hepatoprotective agents and Lactulose",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Standard of care for Cirrhosis management"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "To assess the safety of combination of hematopoetic and mesenchymal stem cell in patients of liver cirrhosis.",
            "PrimaryOutcomeDescription": "Any adverse events after the use of combination stem cell treatment would be recorded:\n\nBone marrow aspiration related complications such as pain (>6 on VAS) and bleeding from the site.\nLeukapheresis related complications such as hypotension and hypocalcemia.\nHepatic artery catheterization related complications such as pain or discomfort at the catheter insertion site, bleeding and infection.\nPost MSC and CD34 infusion related adverse reactions would be recorded using CDSCO form.",
            "PrimaryOutcomeTimeFrame": "Up to 6 months"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Change in MELD (Model for End stage Liver disease) score.",
            "SecondaryOutcomeDescription": "Difference in MELD score from baseline to follow-up period.",
            "SecondaryOutcomeTimeFrame": "Up to 6 months"
          },
          {
            "SecondaryOutcomeMeasure": "Change in Child Pugh score.",
            "SecondaryOutcomeDescription": "Difference in Child Pugh score from baseline to follow-up period.",
            "SecondaryOutcomeTimeFrame": "Up to 6 months"
          },
          {
            "SecondaryOutcomeMeasure": "Change in the percentage of CD 34 cells in liver.",
            "SecondaryOutcomeDescription": "To assess improvement in the percentage of CD 34 cells in liver by performing a paired liver biopsy- before and after infusion.",
            "SecondaryOutcomeTimeFrame": "Up to 6 months"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nAge between 20-70 years\nClinically diagnosed for hepatic cirrhosis having a Child Pugh score of B or MELD >10 but below 20\nNot willing for immediate liver transplantation either due to lack of donor tissue or financial issues\nPlatelet count of > 80,000 and INR <1.6\nLife expectancy of at least 3 months based on MELD score and Child Pugh Score\nAbility to give informed consent\n\nExclusion Criteria:\n\nAge less than 20 or more than 70 years\nHave liver tumors or history of any other cancer\nPregnant or lactating women\nPatients with hepato-renal syndrome and acute kidney injury (Any creatinine > 1.6 will be excluded)\nEvidence of ongoing sepsis - as per Surviving sepsis guideline\nRecent gastrointestinal bleeding or spontaneous bacterial peritonitis (within last one month)\nAny HIV positive patients\nCo-morbid conditions such as severe cardiac and/or pulmonary disease\nInability to give informed consent",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "20 Years",
      "MaximumAge": "70 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "Asian Institute Of Gastroenterology",
            "LocationCity": "Hyderabad",
            "LocationState": "Telangana",
            "LocationZip": "500032",
            "LocationCountry": "India"
          }
        ]
      }
    },
    "ReferencesModule": {
      "ReferenceList": {
        "Reference": [
          {
            "ReferencePMID": "21900788",
            "ReferenceType": "background",
            "ReferenceCitation": "Amer ME, El-Sayed SZ, El-Kheir WA, Gabr H, Gomaa AA, El-Noomani N, Hegazy M. Clinical and laboratory evaluation of patients with end-stage liver cell failure injected with bone marrow-derived hepatocyte-like cells. Eur J Gastroenterol Hepatol. 2011 Oct;23(10):936-41. doi: 10.1097/MEG.0b013e3283488b00."
          },
          {
            "ReferencePMID": "24415865",
            "ReferenceType": "background",
            "ReferenceCitation": "Hang HL, Xia Q. Role of BMSCs in liver regeneration and metastasis after hepatectomy. World J Gastroenterol. 2014 Jan 7;20(1):126-32. doi: 10.3748/wjg.v20.i1.126. Review."
          },
          {
            "ReferencePMID": "16556705",
            "ReferenceType": "background",
            "ReferenceCitation": "Gordon MY, Levicar N, Pai M, Bachellier P, Dimarakis I, Al-Allaf F, M'Hamdi H, Thalji T, Welsh JP, Marley SB, Davies J, Dazzi F, Marelli-Berg F, Tait P, Playford R, Jiao L, Jensen S, Nicholls JP, Ayav A, Nohandani M, Farzaneh F, Gaken J, Dodge R, Alison M, Apperley JF, Lechler R, Habib NA. Characterization and clinical application of human CD34+ stem/progenitor cell populations mobilized into the blood by granulocyte colony-stimulating factor. Stem Cells. 2006 Jul;24(7):1822-30. Epub 2006 Mar 23."
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000008103",
            "ConditionMeshTerm": "Liver Cirrhosis"
          },
          {
            "ConditionMeshId": "D000005355",
            "ConditionMeshTerm": "Fibrosis"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000010335",
            "ConditionAncestorTerm": "Pathologic Processes"
          },
          {
            "ConditionAncestorId": "D000008107",
            "ConditionAncestorTerm": "Liver Diseases"
          },
          {
            "ConditionAncestorId": "D000004066",
            "ConditionAncestorTerm": "Digestive System Diseases"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M10255",
            "ConditionBrowseLeafName": "Liver Cirrhosis",
            "ConditionBrowseLeafAsFound": "Cirrhosis",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M7637",
            "ConditionBrowseLeafName": "Fibrosis",
            "ConditionBrowseLeafAsFound": "Cirrhosis",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M10259",
            "ConditionBrowseLeafName": "Liver Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M8035",
            "ConditionBrowseLeafName": "Gastrointestinal Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M6407",
            "ConditionBrowseLeafName": "Digestive System Diseases",
            "ConditionBrowseLeafRelevance": "low"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC06",
            "ConditionBrowseBranchName": "Digestive System Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC23",
            "ConditionBrowseBranchName": "Symptoms and General Pathology"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          }
        ]
      }
    },
    "InterventionBrowseModule": {
      "InterventionBrowseLeafList": {
        "InterventionBrowseLeaf": [
          {
            "InterventionBrowseLeafId": "M6563",
            "InterventionBrowseLeafName": "Diuretics",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M9962",
            "InterventionBrowseLeafName": "Lactulose",
            "InterventionBrowseLeafRelevance": "low"
          }
        ]
      },
      "InterventionBrowseBranchList": {
        "InterventionBrowseBranch": [
          {
            "InterventionBrowseBranchAbbrev": "All",
            "InterventionBrowseBranchName": "All Drugs and Chemicals"
          },
          {
            "InterventionBrowseBranchAbbrev": "Gast",
            "InterventionBrowseBranchName": "Gastrointestinal Agents"
          }
        ]
      }
    }
  }
}